Treatment for eradication of Helicobacter pylori infection among chronic hepatitis C patients

Norihiro Furusyo, Ahmed H. Walaa, Kunimitsu Eiraku, Kazuhiro Toyoda, Eiichi Ogawa, Hiroaki Ikezaki, Takeshi Ihara, Takeo Hayashi, Mosaburo Kainuma, Masayuki Murata, Jun Hayashi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aims: Helicobacter pylori infection causes gastritis, peptic ulcers and gastric malignancies, and its eradication has been advocated by many groups. We determined the H. pylori carrier status and eradication rates of patients with chronic hepatitis C virus (HCV) infection. Methods: In total, 76 chronically HCV-infected patients were enrolled for comparison with 228 HCV-noninfected, age- and sex-matched controls. H. pylori infection was confirmed by H. pylori antibody and urea breath testing. Results: The H. pylori infection rate was significantly higher for HCV-infected patients (67 of 76, 88.2%) than for HCV-noninfected controls (158 of 228, 69.3%). Endoscopic findings showed that the rates of gastric ulcers and gastritis were significantly higher for the 67 HCV-infected patients with H. pylori infection (34.3% and 77.6%) than for the 158 HCV-noninfected controls with H. pylori infection (15.2% and 57.6%). Treatment to eradicate H. pylori had a significantly higher success rate for HCV-infected patients (61 of 67, 91.0%) than for HCV-noninfected controls (115 of 158, 72.8%). Conclusions: The markedly high H. pylori eradication rate observed in this study shows that eradication of H. pylori holds promise for the improvement of the long-term health condition of patients with chronic HCV infection.

Original languageEnglish
Pages (from-to)447-453
Number of pages7
JournalGut and Liver
Volume5
Issue number4
DOIs
Publication statusPublished - Dec 2011

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Treatment for eradication of Helicobacter pylori infection among chronic hepatitis C patients'. Together they form a unique fingerprint.

  • Cite this